Etoricoxib and Skin Reactions: What You Need to Know About Drug Eruptions
"Discover how a common anti-inflammatory drug can sometimes cause unexpected skin problems and what steps to take if you experience a reaction."
Fixed drug eruption (FDE) is a skin reaction where one or more lesions appear after taking a specific medication. These lesions typically show up as round, reddish, swollen patches that can sometimes blister. While they can occur anywhere on the body, they're more common on the mouth, lips, and genitals. After the first occurrence, these lesions tend to reappear in the same locations with subsequent exposures to the drug, often leaving a dark spot behind.
Non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics are frequently linked to FDE. While oral drug reintroduction is a standard diagnostic test, it can be risky, especially for those with numerous blisters. Even a small dose of the culprit drug might reactivate existing lesions and create new ones.
Patch testing, particularly on previously affected skin, offers a safer alternative, especially when NSAIDs are suspected. This involves applying the suspected drug to the skin to see if a reaction occurs. In a recent case, patch testing helped confirm etoricoxib, a specific NSAID, as the cause of a patient's skin issues.
Reported Etoricoxib Skin Reactions
Etoricoxib has been associated with adverse cutaneous reactions, including fixed drug eruption (FDE). A case report from Thailand described a 37-year-old Thai man who developed erythematous plaques and bullous lesions after taking a 90 mg dose of etoricoxib. FDE is characterized by lesions that recur at the same sites whenever the causative drug is taken, commonly appearing as erythematous round or oval macules or plaques. Oral mucosal involvement is rare, and selective cyclooxygenase-2 inhibitors such as etoricoxib are rarely implicated.
Identifying and Preventing Recurrence
The cited case report emphasizes that identifying, documenting, and analyzing rare adverse drug reactions is important for patient safety and therapeutic decision-making. Identifying the offending drug is described as crucial to preventing progression and recurrence. The report presents etoricoxib-induced fixed drug eruption in a patient receiving long-term therapy, highlighting the practical challenge of recognizing a reaction that may emerge during continued treatment.
A Documented Long-Term Use Case
A case published in the Indian Journal of Pharmacy and Pharmacology identified prolonged etoricoxib use as the likely cause of a fixed drug eruption. After the medication was discontinued, tramadol 40 mg was prescribed for pain relief. Fusidic acid cream was applied locally to support skin recovery. The report underscores the importance of vigilance when NSAIDs such as etoricoxib are used long term.
Etoricoxib and FDE: A Case Study
A 74-year-old woman, who regularly took multiple medications without prior issues, visited the emergency room with a concerning skin reaction. She had a 5cm purplish patch with a central blister on her right-hand finger, along with several smaller red lesions on her upper back and arms.
- Patch Testing Confirms Etoricoxib's Role: Six weeks later, with the skin reaction subsided, patch testing was conducted. This involved applying various allergens, including etoricoxib, to her skin.
- Positive Reaction in Previously Affected Areas: The tests revealed a positive reaction to etoricoxib only in areas where the skin had been previously affected. This confirmed etoricoxib as the cause of her FDE.
- Biopsy Results Support Diagnosis: A skin biopsy from a positive test area showed changes consistent with FDE, further solidifying the diagnosis.
Recent Evidence on Etoricoxib-Associated FDE
A 2025 Thailand case report states that the growing body of case reports involving etoricoxib supports vigilance when prescribing to patients with a history of drug allergies or adverse reactions. Fixed drug eruptions are described as erythematous, violaceous, or vesiculobullous lesions that typically recur at the same site after re-exposure. Lesions may appear 30 minutes to 8 hours after re-exposure, and the reaction is described as a CD8 T-cell-mediated delayed type IV hypersensitivity. Patch testing can help investigate this reaction, although its sensitivity is variable and oral provocation may be required.
Managing and Preventing FDE from Etoricoxib
If you suspect etoricoxib is causing a skin reaction, it's essential to consult with your doctor. They can confirm the diagnosis through patch testing and recommend alternative pain relief options.
Confirmation Through Patient-Specific Testing
A reported case of etoricoxib-induced fixed drug eruption was confirmed by a positive lesional patch test. In that case, lesional patch testing also confirmed an absence of cross-reactivity with celecoxib. A separate report describes seven new cases of etoricoxib-induced fixed eruption diagnosed from their clinical presentation and confirmed by an etoricoxib-positive lesional patch test. These reports illustrate how patient-specific testing can support identification of the responsible medicine and inform future prescribing decisions.
Since cross-reactions can occur with similar drugs, lesional patch testing can help determine safe alternatives. In the case of etoricoxib-induced FDE, patients may be able to safely use other coxibs with different chemical structures. The absence of cross-reactivity with celecoxib, as seen in the case study, offers a viable option.
With increasing medication use, especially among older adults, it's crucial to be aware of potential adverse drug reactions. Identifying the culprit drug is key to preventing future episodes and ensuring patient safety. Always inform your healthcare provider of any unusual symptoms or skin changes after starting a new medication.